title: Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.
abstract: OBJECTIVE
  HCV co-infection is a poor prognostic factor in HIV-1-infected patients. Although the number of newly reported patients who show seroconversion is increasing, the clinical features are still unclear, especially in Asian countries.
  
  
  METHODS
  A single-center retrospective cohort study of patients diagnosed between 2001-2012.
  
  
  METHODS
  Acute hepatitis C (AHC) was diagnosed upon detection of high serum ALT (>100 IU) followed by anti-HCV seroconversion. Clinical characteristics, HIV-1-related immunological status and IL-28B genotypes (rs12979860, rs8099917) were collected. We compared these variables between patients with and without spontaneous clearance of HCV and between responders and non-responders to treatment with pegylated interferon (PEG-IFN) plus ribavirin.
  
  
  RESULTS
  Thirty-five patients were diagnosed with AHC during the study period. The majority (96.9%) were MSM. Three were lost to follow-up. Seventy-five percent of patients with AHC (24/32) were asymptomatic and found incidentally to have high serum ALT. Compared to those who did not show spontaneous clearance, patients with spontaneous HCV viral clearance showed more symptoms and more severe abnormalities related to acute hepatitis. Spontaneous clearance was seen in 4 out of 28 patients with CC+TT genotype, but not in 6 patients with IL-28B CT+TG genotype. PEG-IFN plus ribavirin treatment was initiated in 12 out of 28 cases without spontaneous clearance. The sustained virological response rate was high (81.8%, 9/11), even in cases with CT+TG genotype infected with HCV genotype 1b (SVR 2/2).
  
  
  CONCLUSIONS
  Careful attention to AHC is needed in HIV-1-infected MSM. Early diagnosis and PEG-IFN plus ribavirin treatment should be considered for AHC cases.
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Field Epidemiology Training Program Japan, Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan; Global Infectious Diseases of Infection and Epidemiology, Medical Sciences Doctoral Program, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ishikane
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Watanabe
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Kunihisa
authors.initials: K
authors.lastname: Tsukada
authors.affiliation: Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Nozaki
authors.affiliation: Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Mikio
authors.initials: M
authors.lastname: Yanase
authors.affiliation: Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Igari
authors.affiliation: Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan; Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Naohiko
authors.initials: N
authors.lastname: Masaki
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kikuchi
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
mesh_terms: D000208:Acute Disease; D000328:Adult; D044466:Asian People; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000473:pathology / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D012254:Ribavirin